President Donald Trump recently made headlines when he signed an executive order aimed at lowering the prices of prescription drugs. The order includes a proposal to amend the Medicare drug pricing provision contained in the Inflation Reduction Act, signed into law by former President Biden in 2022. One key aspect of the IRA is the selection and negotiation of a limited subset of pharmaceuticals for price negotiation by the Centers for Medicare and Medicaid Services.
The agency has already chosen the first batch of drugs for negotiation and is set to implement maximum fair prices for these medications in the coming years. However, one contentious issue highlighted by Trump’s executive order is the disparity in the exemption periods for small and large molecule drugs. Small molecule drugs, typically oral medications, currently have a seven-year exemption period, while large molecule biologics, administered through injection, have an 11-year exemption period.
The proposed changes in the executive order could potentially extend the exemption period for small molecules to align with that of biologics, thus eliminating the four-year discrepancy. However, this move has raised concerns within the pharmaceutical industry about the impact it could have on research and development funding.
Moreover, any amendments to the CMS guidance must be budget neutral to ensure that the cost savings envisioned by the IRA are not compromised. This could mean revisiting the maximum fair price ceilings for negotiated drugs to achieve budget neutrality. According to the Kaiser Family Foundation, more than half of the drugs selected for negotiation under the current law would have been ineligible under the proposed changes, potentially affecting widely used medications covered by Medicare.
Another challenge facing the administration is the recent overturning of the Chevron doctrine by the Supreme Court, limiting regulatory agencies’ flexibility in interpreting federal laws. This could pose obstacles to any regulatory changes proposed by the executive branch.
Alternatively, the administration could seek to work with Congress on a legislative solution, such as supporting the Ensuring Pathways to Innovative Cures Act, which aims to extend the negotiation exemption for small molecule drugs. However, passing such legislation may prove difficult given the potential impact on government spending and the widespread support for the current drug price negotiation provision among constituents.
In conclusion, Trump’s executive order on pharmaceutical pricing has sparked a debate on how best to address the issue of prescription drug costs. Whether through regulatory changes, legislative action, or a combination of both, finding a solution that balances cost savings with innovation and access to medications remains a complex challenge.
